There’s information. And then there’s intelligence.

PharmSource’s accurate, insightful Trend Reports provide context and meaning that’s critical to decision-makers in the bio/pharma contract services arena. Our experts identify trends and forecast changes – delivering the knowledge and understanding necessary to achieve optimal strategic outcomes.

Catching a Wave: How Much Will CMOs Benefit From Biosimilars?

Regulatory developments in the United States, coupled with impending patent expiry, have paved the way for the introduction of biosimilars of increasing technical complexity. In the European Union, 20 first wave biosimilars, consisting of growth hormones and relatively simple recombinant proteins, have already been approved. Of those first wave biosimilars…

Learn more

Opportunity Knocks:
In-Licensed Drug Products Can Signal Outsourcing Opportunity

Of the more than 230 New Molecular Entities (NMEs) approved between 2003-2013, over one-third were in-licensed by the sponsor receiving the approval. A significant difference in manufacturing status emerged between…

Learn more

CDMO and CRO Outlook: Robust Market Conditions Augur Growth, More M&A Activity Ahead

Emerging bio/pharmaceutical companies are benefitting from a surge in financing from venture capital, IPOs and secondary offerings. Funding raised in the first half of 2014 is double what was raised in the same period of 2013. R&D spending by global bio/pharma companies, including funds supporting emerging company partners, continues to…

Learn more

Bio/Pharma CapEx Trends: Sponsor Spending on In-House Capacity Trounces Outsourcing

Investment in captive manufacturing capacity by bio/pharma companies is an indicator of the industry’s intentions with respect to outsourcing. Based on recent capital expenditure trends, it’s clear that…

Learn more

European Drug Pricing to Impact CMO Profitability and Performance

This PharmSource Report, Not So NICE: How Market Access Schemes Impact the CMO Sector, presents detailed research and analysis of how European drug-rationing policies could affect pharmaceutical manufacturing profitability – and future operations – in the EU, US and…

Learn more

Future of CMO Cytotoxic Injectables Capacity

This extensive study, The Demand and Supply for Contract Manufacturing of Cytotoxic Injectable Drugs Through 2019, presents a detailed analysis of CMO industry capacity and the projected demand in the next five years and beyond. The research is based on an expert analysis of cytotoxic injectable drugs in the pipeline, including antibody drug conjugates (ADC)s, and…

Learn more